CRSP — CRISPR Therapeutics AG
7 mentions in the last 24 hours · 0.04% of all mentions
Why people talked about CRSP (2026-11-03)
- CRISPR Therapeutics reported Q3 2026 financial results showing revenue of $12.7M and an EPS of -$4.76.
- The FDA granted RMAT designation to CTX310 for treating severe hypertriglyceridemia and elevated LDL-C.
- CTO Sakhamuri Sivakesava filed a Form 3 report indicating no initial stock ownership.
| Bluesky | 5 | community |
| Marketaux | 1 | news |
| SEC EDGAR 8-K | 1 | filings |